Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2009

01-01-2009 | Epidemiology

Stage migration due to introduction of the sentinel node procedure: a population-based study

Authors: A. J. G. Maaskant, L. V. van de Poll-Franse, A. C. Voogd, J. W. W. Coebergh, M. C. B. J. E. Tutein Nolthenius-Puylaert, G. A. P. Nieuwenhuijzen

Published in: Breast Cancer Research and Treatment | Issue 1/2009

Login to get access

Abstract

Background Introduction of sentinel node biopsy (SNB) as an axillary staging procedure in breast cancer patients could have led to upstaging as well as downstaging of their disease. Intensified pathological processing could have led to upstaging due to presence of micrometastases, whereas the described false negative rate of 5% could be a cause of downstaging. We investigated whether or not the introduction of the sentinel node procedure has changed the incidence of axillary nodal micrometastases and induced stage migration on a population based level. Methods Data from the population based Eindhoven Cancer Registry were used on all (n = 17100) women diagnosed with invasive breast cancer in the South-East region of The Netherlands in the period 1994–2005. Results The percentage of patients staged with SNB increased from 0% in 1994 to 62% in 2005. The percentage of patients with micrometastases increased from 1.0% in 1994 to 4.3% in 2005 (P < 0.0001), whereas no significant increase was observed of the proportion of patients with positive axillary lymph nodes. After adjustment for tumor size, age at diagnosis and histology the probability of having a positive axillary lymph node status was 10% higher in period 2003–2005, as compared to period 1994–1996. Furthermore, women diagnosed in the period 2003–2005 had a 3.5 times higher risk of having micrometastases compared to women diagnosed in the period 1994–1996 (i.e., before the introduction of SNB). Conclusion The introduction of SNB in the Southeast region of The Netherlands has led to stage migration, as is reflected by the small but significant increase of the proportion of patients with positive axillary lymph nodes after adjustment for tumor size and age.
Literature
1.
go back to reference van de Vijver MJ, He YD, van’t Veer LJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009PubMedCrossRef van de Vijver MJ, He YD, van’t Veer LJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009PubMedCrossRef
2.
go back to reference Glodhirsch A, Glick JH, Gelber RD, Senn HJ (1998) Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Instit 90:1601–1608CrossRef Glodhirsch A, Glick JH, Gelber RD, Senn HJ (1998) Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Instit 90:1601–1608CrossRef
3.
go back to reference Fisher B, Redmond C, Fisher ER et al (1985) Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Eng J Med 312:674–681CrossRef Fisher B, Redmond C, Fisher ER et al (1985) Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Eng J Med 312:674–681CrossRef
4.
go back to reference Orr RK (1999) The impact of prophylactic axillary node dissection on breast cancer survival - a Bayesian meta-analysis. Ann Surg Oncol 6(1):109–116PubMedCrossRef Orr RK (1999) The impact of prophylactic axillary node dissection on breast cancer survival - a Bayesian meta-analysis. Ann Surg Oncol 6(1):109–116PubMedCrossRef
5.
go back to reference Overgaard M, Jensen MB, Overgaard J et al (1999) Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomized trial. Lancet 353:1641–1648PubMedCrossRef Overgaard M, Jensen MB, Overgaard J et al (1999) Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomized trial. Lancet 353:1641–1648PubMedCrossRef
6.
go back to reference Clarke M, Collins R, Darby S et al (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet 366:2087–2106PubMed Clarke M, Collins R, Darby S et al (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet 366:2087–2106PubMed
7.
go back to reference Voogd AC, Ververs JM, Vingerhoets AJ, Roumen RM, Coebergh JW, Crommelin MA (2003) Lymphoedema and reduced shoulder function as indicators of quality of life after axillary lymph node dissection for invasive breast cancer. Br J Surg 90(1):76–81PubMedCrossRef Voogd AC, Ververs JM, Vingerhoets AJ, Roumen RM, Coebergh JW, Crommelin MA (2003) Lymphoedema and reduced shoulder function as indicators of quality of life after axillary lymph node dissection for invasive breast cancer. Br J Surg 90(1):76–81PubMedCrossRef
8.
go back to reference Ververs JM, Roumen RM, Vingerhoets AJ et al (2001) Risk, severity and predictors of physical and psychological morbidity after axillary lymph node dissection for breast cancer. Eur J Cancer 37(8):991–999PubMedCrossRef Ververs JM, Roumen RM, Vingerhoets AJ et al (2001) Risk, severity and predictors of physical and psychological morbidity after axillary lymph node dissection for breast cancer. Eur J Cancer 37(8):991–999PubMedCrossRef
9.
go back to reference Cox CE, Bass SS, McCann CR et al (2000) Lymphatic mapping and sentinel lymph node biopsy in patients with breast cancer. Annu Rev Med 51:525–542PubMedCrossRef Cox CE, Bass SS, McCann CR et al (2000) Lymphatic mapping and sentinel lymph node biopsy in patients with breast cancer. Annu Rev Med 51:525–542PubMedCrossRef
10.
go back to reference Veronesi U, Paganelli G, Galimberti V et al (1997) Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymphnodes. Lancet 349:1864–1867PubMedCrossRef Veronesi U, Paganelli G, Galimberti V et al (1997) Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymphnodes. Lancet 349:1864–1867PubMedCrossRef
11.
go back to reference Schijven MP, Vingerhoets AJ, Rutten HJ et al (2003) Comparison of morbidity between axillary lymph node dissection and sentinel node biopsy. Eur J Surg Oncol 29(4):341–350PubMedCrossRef Schijven MP, Vingerhoets AJ, Rutten HJ et al (2003) Comparison of morbidity between axillary lymph node dissection and sentinel node biopsy. Eur J Surg Oncol 29(4):341–350PubMedCrossRef
12.
go back to reference Krag D, Weaver D, Ashikaga T et al (1998) The sentinel node in breast cancer—a multicenter validation study. N Eng J Med 339(14):941–946CrossRef Krag D, Weaver D, Ashikaga T et al (1998) The sentinel node in breast cancer—a multicenter validation study. N Eng J Med 339(14):941–946CrossRef
13.
go back to reference Tjan-Heijnen VC, Bult P, de Widt-Levert LM, Ruers TJ, Beex LV (2001) Micro-metastases in axillary lymph nodes: an increasing classification and treatment dilemma in breast cancer due to the introduction of the sentinel lymph node procedure. Breast Cancer Res Treat 70(2):81–88PubMedCrossRef Tjan-Heijnen VC, Bult P, de Widt-Levert LM, Ruers TJ, Beex LV (2001) Micro-metastases in axillary lymph nodes: an increasing classification and treatment dilemma in breast cancer due to the introduction of the sentinel lymph node procedure. Breast Cancer Res Treat 70(2):81–88PubMedCrossRef
14.
go back to reference Lyman GH, Giuliani AE, Somerfiedl MR et al (2005) American Society of Clinical Oncology Guideline Recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 23(30):7703–7720PubMedCrossRef Lyman GH, Giuliani AE, Somerfiedl MR et al (2005) American Society of Clinical Oncology Guideline Recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 23(30):7703–7720PubMedCrossRef
15.
go back to reference Edge SB, Niland JC, Bookman MA et al (2003) Emergence of sentinel node biopsy in breast cancer as standard-of-care in academic comprehensive cancer centers. J Natl Cancer Inst 95(20):1415–1521 Edge SB, Niland JC, Bookman MA et al (2003) Emergence of sentinel node biopsy in breast cancer as standard-of-care in academic comprehensive cancer centers. J Natl Cancer Inst 95(20):1415–1521
16.
go back to reference Hermanek P, Sobin LH, eds (1987) UICC TNM classification of malignant tumors. Springer-Verlag, Berlin, pp 94–99 Hermanek P, Sobin LH, eds (1987) UICC TNM classification of malignant tumors. Springer-Verlag, Berlin, pp 94–99
18.
go back to reference Bostick PJ, Huynh KT, Sarantou T et al (1998) Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple-marker RT-PCR. Int J Cancer 79(6):645–651PubMedCrossRef Bostick PJ, Huynh KT, Sarantou T et al (1998) Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple-marker RT-PCR. Int J Cancer 79(6):645–651PubMedCrossRef
19.
go back to reference Roumen RMH, Pijpers HJ, Thunnisen FBJM, Ruers TJM (2000) Samenvatting van de richtlijn “Schildwachtklierbiopsie bij mammacarcinoom”. Ned Tijdschr Geneeskd 144:1864–1867PubMed Roumen RMH, Pijpers HJ, Thunnisen FBJM, Ruers TJM (2000) Samenvatting van de richtlijn “Schildwachtklierbiopsie bij mammacarcinoom”. Ned Tijdschr Geneeskd 144:1864–1867PubMed
20.
go back to reference Giuliano A, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL (1995) Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 222(3):394–399PubMedCrossRef Giuliano A, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL (1995) Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 222(3):394–399PubMedCrossRef
21.
go back to reference van der Heiden-van der Loo M, Bezemer PD, Hennipman A et al (2006) Introduction of sentinel node biopsy and stage migration of breast cancer. Eur J Surg Oncol 32(7):710–714 van der Heiden-van der Loo M, Bezemer PD, Hennipman A et al (2006) Introduction of sentinel node biopsy and stage migration of breast cancer. Eur J Surg Oncol 32(7):710–714
22.
go back to reference Kuijt GP, van de Poll-Franse LV, Voogd AC, Nieuwenhuijzen GAP, Roumen RMH (2007) Survival after negative sentinel lymph node biopsy in breast cancer at least equivalent to after negative extensive axillary dissection. Eur J Surg Oncol 33(7):832–837PubMed Kuijt GP, van de Poll-Franse LV, Voogd AC, Nieuwenhuijzen GAP, Roumen RMH (2007) Survival after negative sentinel lymph node biopsy in breast cancer at least equivalent to after negative extensive axillary dissection. Eur J Surg Oncol 33(7):832–837PubMed
23.
go back to reference Vanderveen KA, Schneider PD, Khatri VP, Goodnight JE, Bold RJ (2006) Upstaging and improved survival of early breast cancer patients after implementation of sentinel node biopsy for axillary staging. Ann Surg Oncol 13(11):1450–1456PubMedCrossRef Vanderveen KA, Schneider PD, Khatri VP, Goodnight JE, Bold RJ (2006) Upstaging and improved survival of early breast cancer patients after implementation of sentinel node biopsy for axillary staging. Ann Surg Oncol 13(11):1450–1456PubMedCrossRef
Metadata
Title
Stage migration due to introduction of the sentinel node procedure: a population-based study
Authors
A. J. G. Maaskant
L. V. van de Poll-Franse
A. C. Voogd
J. W. W. Coebergh
M. C. B. J. E. Tutein Nolthenius-Puylaert
G. A. P. Nieuwenhuijzen
Publication date
01-01-2009
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-008-9913-8

Other articles of this Issue 1/2009

Breast Cancer Research and Treatment 1/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine